Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma

References

• Ries L AG, Kosary C I, Hankey B F, et al. SEER Cancer Statistics Review, 1973 – 1996. National Cancer Institute, Bethesda, MD 1999
   Google Scholar
• Gómez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352–2358
   PubMed Web of Science ®Google Scholar
• Lyman G H, Kuderer N M, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 2002; 9: 207–214
   PubMed Web of Science ®Google Scholar
• Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002; 3: 289–297
   PubMed Web of Science ®Google Scholar
• Repetto L, Biganzoli L, Koehne C H, et al. EORTC cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003; 39: 2264–2272
   PubMed Web of Science ®Google Scholar
• McKelvey E M, Gottleib J A, Wilson H E, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Coltman C A, Dahlberg S, Jones S E, . SWOG studies in diffuse large cell lymphoma: a subset analysis. Cancer chemotherapy: Challenges for the future, K Kimura, et al. Excerpta Medica, TokyoJapan 1988; 194–202
   Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Cooper I A, Wolf M M, Robertson T I, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Kouroukis C T, Browman G P, Esmail R, Meyer R M. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 2002; 136: 144–152
   PubMed Web of Science ®Google Scholar
• Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24(4 Suppl 10)S10-3–S10-10
   Web of Science ®Google Scholar
• Pfreundschuh M, Truemper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Green M D, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Clopper C J, Pearson E S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413
   Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101: 3840–3848
   PubMed Web of Science ®Google Scholar
• Gregory S A, Case D C, Jr, Bosserman L, et al. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Clin Lymphoma 2003; 4: 93–98
   PubMedGoogle Scholar
• Yu J, Leisenring W, Bensinger W I, et al. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999; 39: 442–450
   PubMed Web of Science ®Google Scholar
• Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30(4 Suppl 13)24–30
   PubMed Web of Science ®Google Scholar
• Armitage J, Potter J. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Donnelly G B, Glassman J, Long C, et al. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leuk Lymphoma 2000; 39: 26–75
   Web of Science ®Google Scholar
• Ozer H, Armitage J O, Bennett C L, et al. for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558–3585
   PubMed Web of Science ®Google Scholar